Off-topic for aiqbench
This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.
What a desert lizard teaches us about patents and the GLP-1 revolution
The GLP-1 story shows how patents can reward discovery and push rivals to develop better drugs.
After steadily rising for decades, America’s obesity rate is finally declining. It peaked in 2022, when 39.9% of adults were obese, according to Gallup. This year, that share dipped to 36.4% — in large part thanks to increasingly widespread GLP-1 weight-loss medicines. About one in every nine adults currently takes Wegovy, Zepbound, or another GLP-1. That’s roughly a ten-fold increase since 2022. And that share will likely keep rising as the price of these drugs continues to drop. As recently…
Excerpt shown under the publisher's RSS terms · 80 words · full text and figures are on the publisher's site
